Welcome to our dedicated page for Utah Med Prods news (Ticker: UTMD), a resource for investors and traders seeking the latest updates and insights on Utah Med Prods stock.
Utah Medical Products Inc. develops, manufactures and markets disposable and reusable specialty medical devices, with a stated focus on health care for women and babies. Its products are used in areas such as blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology and urology, serving hospitals, outpatient clinics and physicians' offices.
Company updates commonly cover quarterly and annual financial performance, domestic and outside-U.S. sales trends, foreign-currency effects, product-category demand, OEM and distributor relationships, and profit margins. Recurring corporate actions include quarterly cash dividends, open-market share repurchases when disclosed, board appointments and other governance updates for the Nasdaq-listed common stock.
Utah Medical Products (NASDAQ:UTMD) has declared a quarterly cash dividend of $0.28 per share, to be paid on October 5, 2020, to shareholders on record as of September 15, 2020. This marks a 2% increase over the previous year's dividend for the same quarter. The company specializes in healthcare solutions for women and infants and is recognized for its specialty medical devices used globally. This dividend decision reflects the company's ongoing financial commitment to its shareholders.
Utah Medical Products, Inc. (NASDAQ:UTMD) announced a quarterly cash dividend of $0.28 per share, set to be paid on October 5, 2020. This marks a 2% increase from the previous year's dividend issued in the same quarter. Shareholders on record as of September 15, 2020 will be eligible for this payment. The company focuses on developing and marketing specialty medical devices aimed at enhancing healthcare outcomes for women and infants worldwide.
On July 28, 2020, Utah Medical Products reported significant declines in financial performance for Q2 and H1 2020, attributed mainly to the COVID-19 pandemic affecting elective medical procedures. Q2 sales dropped by 26%, with gross profit declining 34%. Operating income fell by 56%, resulting in a net income decrease of 63%. Despite these challenges, the company maintains strong financial stability, with cash reserves of $42.4 million and continued profitability during the shutdown. Management anticipates a recovery driven by government policy responses.